Table 1. Compound effect on OPC metabolic activity.
| Category | Compound | Average | SD |
|---|---|---|---|
| VASODILATOR | VINPOCETINE | 1.36 | 0.66 |
| ISOXSUPRINE | 1.54 | 0.23 | |
| NYLIDRIN | 1.60 | 0.00 | |
| STEROIDS | CYPROTERONE | 1.29 | 0.38 |
| CHLORMADINONE ACETATE | 1.69 | 0.30 | |
| ESTRADIOL (2X) | 1.30 | 0.17 | |
| FLUDROCORTISONE ACETATE | 1.35 | 0.05 | |
| FLAVONOIDS | BIOCHANIN A | 2.13 | 0.29 |
| QUERCITRIN | 1.40 | 0.29 | |
| 5-METHYL-7-METHOXYISOFLAVONE | 1.53 | 0.23 | |
| ANTIHYPERTENSIVE ACE INHIBITOR | PERINDOPRIL ERBUMINE | 1.30 | 0.21 |
| TRANDOLAPRIL | 1.30 | 0.13 | |
| ANTIHYPERTENSIVE SARTAN | LOSARTAN | 1.30 | 0.18 |
| OLMESARTAN | 1.31 | 0.17 | |
| ANTIHYPERTENSIVE DIURETIC | DIAZOXIDE | 1.32 | 0.05 |
| VERATRINE SULFATE | 1.40 | 0.20 | |
| ANTIHYPERTENSIVE β-BLOCKER | ALPRENOLOL | 1.37 | 0.25 |
| ANTIINFLAMMATORY | HYDROXYTOLUIC ACID | 1.33 | 0.06 |
| S-(1,2-DICARBOXYETHYL)GLUTATHIONE | 1.32 | 0.21 | |
| VULPINIC ACID | 1.37 | 0.35 | |
| DIACERIN | 1.33 | 0.06 | |
| FLUOCINOLONE ACETONIDE | 1.40 | 0.30 | |
| BECLOMETHASONE DIPROPIONATE | 1.51 | 0.14 | |
| ANTIBACTERIC | FENAMISAL | 1.33 | 0.21 |
| KANAMYCIN A SULPHATE | 1.32 | 0.03 | |
| GENTAMICIN SULPHATE | 1.44 | 0.15 | |
| HYGROMYCIN B | 1.33 | 0.25 | |
| ANTIHISTAMINIC | TRIPELENNAMINE CITRATE | 1.40 | 0.26 |
| DIPHENYLPYRALINE HYDROCHLORIDE | 1.48 | 0.16 | |
| ORPHENADRINE CITRATE | 1.49 | 0.14 | |
| ANTI-DEPRESSIVE | ESCITALOPRAM OXALATE | 1.43 | 0.12 |
| ANTIOXIDANT | EDARAVONE | 1.33 | 0.15 |
| MUSCARINIC ANTAGONIST | HYOSCYAMINE | 1.53 | 0.12 |
| HYPOLIPIDEMIC | LOVASTATIN | 1.23 | 0.10 |
| NIACIN | 1.47 | 0.06 | |
| CATHARTIC | PHENOLPHTHALEIN | 1.67 | 0.29 |
| COMT INHIBITOR | 3,5-DINITROCATECHOL (OR-486) | 1.37 | 0.06 |
| MUSCARINIC AGONIST | AMINOBENZTROPINE | 1.33 | 0.06 |
| PSYCHOSTIMULANT | URIDINE TRIPHOSPHATE TRISODIUM | 1.40 | 0.10 |
| ANTI-INFECTIVE | CINEOLE | 1.38 | 0.35 |
| ANTIARYTHMIC | LIDOCAINE HYDROCHLORIDE | 1.55 | 0.21 |
| LIPASE INHIBITOR | ORLISTAT | 1.32 | 0.21 |
| ANTIFUNGAL | AVOCADYNE ACETATE | 1.43 | 0.12 |
All 2,000 compounds of the library were screened blind by MTT assay in purified OPC cultures; table shows compound names and pharmacological categories of the 42 more active compounds. MTT value was quantified by an Efficacy Ratio defined as: ER = absorbance of drug/absorbance of untreated control. The 42 drugs showing a mean value of ER ≥ 1.3 and suitable for human use in their present chemical form were selected. Lovastatin, a drug that presented a mean value of ER = 1.23 ± 0.1 was added to this list because of the demonstrated activity of this compound on OPC differentiation and myelin formation and used as internal control of the screening.